191 related articles for article (PubMed ID: 29982521)
41. The antibiotic pipeline: reviving research and development and speeding drugs to market.
Luepke KH; Mohr JF
Expert Rev Anti Infect Ther; 2017 May; 15(5):425-433. PubMed ID: 28306360
[TBL] [Abstract][Full Text] [Related]
42. The U.S. vaccine supply.
Schwartz HK
N Engl J Med; 2005 Mar; 352(10):1046-7; author reply 1046-7. PubMed ID: 15762001
[No Abstract] [Full Text] [Related]
43. Public sector seeks to bridge 'valley of death'.
Moran N
Nat Biotechnol; 2007 Mar; 25(3):266. PubMed ID: 17344867
[No Abstract] [Full Text] [Related]
44. Europe bets on drug discovery.
Baker M
Nature; 2013 Feb; 494(7435):20. PubMed ID: 23393658
[No Abstract] [Full Text] [Related]
45. Public-private partnership models in France and in Europe.
Demotes-Mainard J; Canet E; Segard L
Therapie; 2006; 61(4):325-34, 313-23. PubMed ID: 17124948
[TBL] [Abstract][Full Text] [Related]
46. Should financial incentives be used to differentially reward 'me-too' and innovative drugs?
Pekarsky B
Pharmacoeconomics; 2010; 28(1):1-17. PubMed ID: 20014872
[TBL] [Abstract][Full Text] [Related]
47. Is there transparency in the pricing of medicines in the South African private sector?
Bangalee V; Suleman F
S Afr Med J; 2018 Feb; 108(2):82-83. PubMed ID: 29429435
[TBL] [Abstract][Full Text] [Related]
48. A breakthrough in R&D for neglected diseases: new ways to get the drugs we need.
Moran M
PLoS Med; 2005 Sep; 2(9):e302. PubMed ID: 16138789
[TBL] [Abstract][Full Text] [Related]
49. Resisting antimicrobial resistance.
Nathan C
Nat Rev Microbiol; 2020 May; 18(5):259-260. PubMed ID: 32300248
[No Abstract] [Full Text] [Related]
50. [Open innovation: public-private partnerships in pharmaceutical R&D].
Uchibayashi N
Nihon Yakurigaku Zasshi; 2013 Jul; 142(1):32-8. PubMed ID: 23842226
[No Abstract] [Full Text] [Related]
51. The global drug gap.
Reich MR
Science; 2000 Mar; 287(5460):1979-81. PubMed ID: 10755953
[TBL] [Abstract][Full Text] [Related]
52. [Competition and prices in the Mexican pharmaceutical market].
Molina-Salazar RE; González-Marín E; Carbajal-de Nova C
Salud Publica Mex; 2008; 50 Suppl 4():S496-503. PubMed ID: 19082261
[TBL] [Abstract][Full Text] [Related]
53. Back to irrational exuberance.
Laster L
Hosp Pract (1995); 2001 Jul; 36(7):9-10. PubMed ID: 11446602
[No Abstract] [Full Text] [Related]
54. Pay drug companies $1bn for each new antibiotic, says report.
Owen J
BMJ; 2016 May; 353():i2863. PubMed ID: 27198868
[No Abstract] [Full Text] [Related]
55. Pharmacoeconomics in the years of crisis: a solution or just a resolution? A Cyprus perspective.
Petrou P
Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):627-36. PubMed ID: 24953125
[TBL] [Abstract][Full Text] [Related]
56. Funding pharmaceutical innovation through direct tax credits.
Lybecker KM; Freeman RA
Health Econ Policy Law; 2007 Jul; 2(Pt 3):267-84. PubMed ID: 18634650
[TBL] [Abstract][Full Text] [Related]
57. Transnational capital and confessional politics: the paradox of the health care system in Lebanon.
Sen K; Mehio-Sibai A
Int J Health Serv; 2004; 34(3):527-51. PubMed ID: 15346684
[TBL] [Abstract][Full Text] [Related]
58. A source of innovation.
Gillespie DG
Integration; 1992 Dec; (34):2-7. PubMed ID: 12317827
[TBL] [Abstract][Full Text] [Related]
59. Into the valley of death: research to innovation.
Hudson J; Khazragui HF
Drug Discov Today; 2013 Jul; 18(13-14):610-3. PubMed ID: 23402848
[TBL] [Abstract][Full Text] [Related]
60. In the midst of the antimicrobial discovery conundrum: an overview.
Tomaras AP; Dunman PM
Curr Opin Microbiol; 2015 Oct; 27():103-7. PubMed ID: 26356257
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
